Of the 399 senior executives in the life sciences industry surveyed by the Economist Intelligence Unit (EIU) recently, 64% of respondents said that demonstrating value is a key challenge facing their business. The major issue, most agree, is that stakeholders have different perceptions of what value is.
Of the 399 senior executives in the life sciences industry surveyed by the Economist Intelligence Unit (EIU) recently, 64% of respondents said that demonstrating value is a key challenge facing their business. The major issue, most agree, is that stakeholders have different perceptions of what value is.
The Quintiles-sponsored report, Reinventing Biopharma, found that most pharma companies have made at least one change to their business model, commercial and/or R&D strategy to meet this ‘value challenge’; many are accepting that the demand to provide value has had an important or significant impact on their business model and are “coordinating the response to the challenge across the company”.
Dr Adrian Thomas, VP for Market Access at Janssen, for example, said that the company’s R&D organization has developed a “fairly solid understanding of payer value”. He explained: “Clinical evidence and regulatory hurdles are still crucial, but equally important are commercial considerations that products will meet other thresholds of acceptability…We have the value question as a critical piece of decision making. That is a huge departure from three to five years ago.”
But there remains little convergence in dealing with the value question; no single strategy is emerging as a majority favourite. As Dr Ed Pezalla of Aetna comments, while many players are aware of the issue, “substantial change still has to take place”.
Until then, demonstrating value will very much remain a challenge for the industry.
Reinventing Biopharma: the value challenge, is available here.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.